Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (159) Apply Press releases filter
- Basic page (28) Apply Basic page filter
- Pipeline (19) Apply Pipeline filter
- Corporate presentations (16) Apply Corporate presentations filter
- Shareholder meeting (16) Apply Shareholder meeting filter
- Team member (15) Apply Team member filter
- Videos (14) Apply Videos filter
- Financial reports (9) Apply Financial reports filter
- Analyst (6) Apply Analyst filter
- Webcasts and audio (5) Apply Webcasts and audio filter
- Event (3) Apply Event filter
- Investor contact (3) Apply Investor contact filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics
Oxford, UK & London, UK– 29 November 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene
Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting
Oxford, UK & London, UK– 5 December 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene
Oxford BioMedica Announces Publication of Pioneering RetinoStat® (OXB-201) Phase I Study Data in the Journal, Human Gene Therapy
-- RetinoStat® met its primary endpoint, demonstrating favourable safety and tolerability profiles
Oxford BioMedica Result of General Meeting and Directors Dealing
London, UK – 29 September 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell thera
Interim Results for the six months ended 30 June 2016
Oxford BioMedica plc
Interim Results for the six months ended 30 June 2016